Free Trial
NYSEAMERICAN:VNRX

VolitionRx (VNRX) Stock Price, News & Analysis

VolitionRx logo
$0.48 -0.01 (-2.56%)
As of 05/2/2025 04:10 PM Eastern

About VolitionRx Stock (NYSEAMERICAN:VNRX)

Key Stats

Today's Range
$0.48
$0.51
50-Day Range
$0.46
$0.59
52-Week Range
$0.42
$0.91
Volume
120,723 shs
Average Volume
159,477 shs
Market Capitalization
$30.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Stock News Headlines

VolitionRX Signs New Capital Sales Agreement
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
VolitionRX Stock Price, Quotes and Forecasts
VolitionRx reports results from Nu.Q Cancer test
See More Headlines

VNRX Stock Analysis - Frequently Asked Questions

VolitionRx's stock was trading at $0.58 at the beginning of 2025. Since then, VNRX stock has decreased by 18.1% and is now trading at $0.4750.
View the best growth stocks for 2025 here
.

VolitionRx Limited (NYSEAMERICAN:VNRX) announced its quarterly earnings results on Wednesday, November, 10th. The medical research company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The medical research company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. VolitionRx had a negative trailing twelve-month return on equity of 15,493.47% and a negative net margin of 9,158.31%.

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Exelixis (EXEL), T2 Biosystems (TTOO) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
11/10/2021
Today
5/05/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:VNRX
Previous Symbol
NYSEMKT:VNRX
Employees
80
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-30,270,000.00
Net Margins
-9,158.31%
Pretax Margin
-9,257.43%
Return on Equity
-15,493.47%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Price / Cash Flow
N/A
Book Value
($0.05) per share
Price / Book
-9.50

Miscellaneous

Free Float
53,450,000
Market Cap
$30.01 million
Optionable
Not Optionable
Beta
1.59
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NYSEAMERICAN:VNRX) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners